Appointment of a Director and Share Options

RNS Number : 6989M

Eden Research plc

11 May 2015

 

Eden Research plc

("Eden" or "Company")

Appointment of a Director and Share Options

Eden Research Plc (AIM: EDEN), the AIM-listed natural micro-encapsulation company, announces that it has appointed Robin James Scott Cridland as a Non-Executive Director with effect from 8 May 2015. Mr Cridland has over 20 years of experience in senior management and transactional roles in the international pharmaceutical and technology sectors, including serving on the boards of listed companies as an executive director.

Mr Cridland, aged 47, currently serves as Chief Financial Officer and Company Secretary of Revolymer plc. He joined Revolymer in September 2008 from Renovo Group plc where he spent seven years as Executive Director of Finance and Business Development. He has been centrally involved in the listing of both businesses and in a number of significant licences and other product commercialisation deals. Mr Cridland has a first-class honours degree in Natural Sciences from the University of Oxford and is a Fellow of the Institute of Chartered Accountants in England and Wales.

He began his career at Coopers & Lybrand Deloitte, before moving on to senior transactional roles at Enskilda Securities and senior finance and transactional roles at GlaxoWellcome and GlaxoSmithKline. He is also currently a Governor and a Non-Executive Director of Cheadle Hulme School, Cheshire.

Tom Lupton, Chairman of Eden said: "We are very pleased to welcome Rob to the Board, and we look forward to his contributions as a Non-Executive Director. Rob's education, background and experience are perfectly matched to Eden's overall business as a technology licensing company."

Rob Cridland said: "I am delighted to be joining Eden Research at such a pivotal time. The business is in the process of transitioning from a development stage company towards significant commercial milestones. I hope that my own experience in both IP licensing and operating listed businesses will enable me to make a constructive contribution to Eden's Board."

Current directorships	Previous directorships
Revolymer Plc	Renovo Group Plc
Revolymer UK Limited
Revolymer (US) Inc.
Revolymer EBT Limited
Cheadle Hulme School

There is no further information to be disclosed in accordance with paragraph (g) Schedule Two, Aim Rules for Companies

Grant of Share Options

Alex Abrey, Chief Financial Officer, has been granted 125,000 share options with effect from the 8 of May 2015 at an exercise price of 10.375 pence and an expiry date of 30 April 2018.

Enquiries:

Eden Research plc	www.edenresearch.com
Sean Smith, Chief Executive Officer	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	www.wh-ireland.co.uk
John Wakefield / Ed Allsopp	Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCAPMATMBIMBPA